Zimmer Biomet Eyes Faster Growth in 2027, Targets Earlier Robotics Launch

Zimmer Biomet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zimmer Biomet expects revenue growth to accelerate in 2027, citing a China headwind that may turn into a tailwind, new products and progress in its U.S. sales-force transition.
  • The company has submitted its Monogram surgical robotics platform for FDA clearance and aims to launch it in 2027—earlier than previously expected—pending review.
  • Third-quarter results were mixed: technology revenue rose 24% and global hip revenue grew 7%, while U.S. knee revenue fell 2% amid changes to the sales model.
  • MarketBeat previews top five stocks to own in December.

Zimmer Biomet NYSE: ZBH expects revenue growth to improve in 2027 after exceeding its own expectations in each of the first three quarters of 2026, CEO Ivan Tornos said during a Jefferies fireside chat.

Tornos pointed to a diminishing headwind in China, progress in the company’s U.S. sales force transition and new product launches as potential contributors. He also announced that Zimmer Biomet had filed a 510(k) submission with the U.S. Food and Drug Administration for its Monogram surgical robotics platform.

“Our expectations are we’re going to be launching in the year 2027,” Tornos said of Monogram, while noting that the launch depends on the FDA’s review. He said the company expects to introduce it as a surgeon-guided autonomous platform sooner than the 2028 timeframe it had previously contemplated.

Third-quarter growth and knee performance

Tornos said global hip revenue grew 7% in the third quarter, including 5.8% growth in the U.S. and 8.2% outside the country. The company’s SET businesses grew 7.1% globally, with foot and ankle growth of 18.4% and CMFT growth of 15%.

Technology revenue grew 24% for the quarter, including 34.6% in the U.S., he said. Zimmer Biomet reports technology alongside surgical and other revenue.

Knees were a weaker area. Tornos said changes to the U.S. go-to-market model affected the franchise, contributing to a 2% decline in U.S. knee revenue. He said knee revenue would have been flat globally excluding China.

Zimmer Biomet continues to estimate its weighted average market growth rate at 4.25%, Tornos said. Although the U.S. reconstructive market was slightly softer than expected in the quarter, he said indicators such as cancellation rates, waiting lists and referral cycles had not shown evidence of a structural change in market growth.

Monogram and iodine-coated implants

Tornos said the Monogram submission followed a clinical trial that reported zero safety events. He described potential advantages in efficiency, ease of use, reproducibility and accuracy, while cautioning that the company must obtain the FDA claims it is seeking. He said he would not be surprised by further exchanges with the agency during its review.

The company is also looking to expand its iodine-coated implant technology beyond Japan, where it has launched a coated hip device. Tornos said the product has contributed to hip growth and carries a 40% premium when customers move from a non-coated device to an iodine-coated one.

Zimmer Biomet is working toward European authorization and discussing opportunities in the U.S. and Canada, he said. The company also intends to extend the technology to knee and shoulder products.

2027 outlook and acquisition strategy

Tornos said China represented a 50-basis-point headwind to company growth in 2026, but he expects it to become a tailwind in 2027. He also cited a full year of Paragon 28 in organic growth, the ROSA Shoulder platform and a potential Monogram launch as factors supporting the outlook.

He cautioned that the final stage of the U.S. sales force transition remains the riskiest. Of Zimmer Biomet’s 2,540 U.S. representatives, 75% now work exclusively for the company, Tornos said. The company plans to continue the transition through 2027.

Zimmer Biomet aims to raise its weighted average market growth rate to 6% by 2030. Tornos said the company believes it can achieve about half of the required increase organically, with acquisitions providing the rest. He identified higher-growth reconstructive products, SET, neuro and ambulatory surgery center opportunities as areas of interest.

Margins and cash flow

Interim CFO Paul Stellato said revenue growth, manufacturing footprint changes and inventory simplification could support longer-term gross margin expansion. He noted that Zimmer Biomet had announced a Swiss facility shutdown and opened a Costa Rica facility earlier in the year.

Stellato also said the company’s 46.5% operating expense profile was not sustainable, and pointed to technology and a global capability center in India as potential sources of efficiency.

Tornos said Zimmer Biomet expects to generate close to $2 billion in operating cash flow and roughly $1.3 billion to $1.4 billion in free cash flow for 2026. The company plans to prioritize a stable dividend, strategic acquisitions and share repurchases, including close to $500 million in buybacks in the fourth quarter, he said.

About Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zimmer Biomet Right Now?

Before you consider Zimmer Biomet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.

While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines